A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy - Wikidata - wikimedia - TriplyDB

A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy

A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy

http://www.wikidata.org/entity/Q28475529

about

EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors Anticancer efficacy of a nitric oxide-modified derivative of bifendate against multidrug-resistant cancer cells Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells Gene silencing of FANCF potentiates the sensitivity to mitoxantrone through activation of JNK and p38 signal pathways in breast cancer cells Overexpression of asparagine synthetase and matrix metalloproteinase 19 confers cisplatin sensitivity in nasopharyngeal carcinoma cells.An Acetamide Derivative as a Camptothecin Sensitizer for Human Non-Small-Cell Lung Cancer Cells through Increased Oxidative Stress and JNK Activation.ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer.Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.Human ABCG2: structure, function, and its role in multidrug resistance.Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics.Targeting cancer stem cell-specific markers and/or associated signaling pathways for overcoming cancer drug resistance.MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).Tumor heterogeneity of gastric cancer: From the perspective of tumor-initiating cell.

P2860

Q27318449-564E53D4-06C8-47A4-A1EC-575C129DCC1B Q28468523-D9C021B2-7F0D-4297-9C52-302BE9284083 Q28476445-E478AC33-5061-4E71-BBBE-AEB3D43D07FD Q34406515-0D18F773-0126-4635-BBB9-6E763A0A8EC1 Q37227757-75796F95-C378-44F2-B01F-933F2A385F0A Q37397101-6F3420B3-1D8E-4DE0-90B8-DB9B77D93967 Q37595188-D344A8AD-FFD4-4831-A543-3A9D89C8DFF8 Q37958162-ACB04537-EE80-48BD-8F99-D732C8D8F0F7 Q38003156-21EE6A95-521A-4D02-AD55-A5AD4C4438AE Q38207943-A6C4C714-1F2F-4500-A5E4-F8708045C18C Q38937280-6851D4BA-0C77-4252-AC12-6989D4512E74 Q39137771-D3CA0DD8-EBE9-40B5-A46C-5402DDA751B6 Q55365203-3287B1B1-68BF-47C3-909F-1B6D8DA18145

P2860

A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy

http://www.wikidata.org/entity/Q28475529

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

A novel two mode-acting inhibi ...... istance in cancer chemotherapy

@ast

A novel two mode-acting inhibi ...... istance in cancer chemotherapy

@en

A novel two mode-acting inhibi ...... istance in cancer chemotherapy

@nl

type

label

A novel two mode-acting inhibi ...... istance in cancer chemotherapy

@ast

A novel two mode-acting inhibi ...... istance in cancer chemotherapy

@en

A novel two mode-acting inhibi ...... istance in cancer chemotherapy

@nl

prefLabel

A novel two mode-acting inhibi ...... istance in cancer chemotherapy

@ast

A novel two mode-acting inhibi ...... istance in cancer chemotherapy

@en

A novel two mode-acting inhibi ...... istance in cancer chemotherapy

@nl

P1433

Q28475529-6F1696D8-4ED1-4C6A-9BE7-31EEFDF48E6E

P1476

Q28475529-2E0CEC15-EFFC-4A1A-B575-604DF44A1D90

P2093

Q28475529-14F5179C-4CDE-4DB9-BCC0-F0F8004C02D7

Q28475529-30FD7121-618F-42AB-8282-3AF1EBBEDB24

Q28475529-3FF67657-619C-4DFD-A36F-4511DBDD6F79

Q28475529-6F3CE485-0779-4746-9072-52EEFE973708

Q28475529-8AE89C0B-4AAB-4858-9407-01979A604C87

Q28475529-93D7DE7C-ECB8-434D-925C-3B6FE562A614

Q28475529-9F586A4F-FF58-48F5-943A-C39640DD994C

Q28475529-AB94D774-0AA3-4F3B-BE1D-FC4D3E43F43E

P2860

Q28475529-02F572E2-0CA6-476E-9233-CAD56EB88B72

Q28475529-04AC3A24-98C3-476D-A1C4-DC12B4CC73DB

Q28475529-14DDCDDF-D854-47B8-A9AA-99110A490C7B

Q28475529-1AE7BCF4-1D9F-4537-93F7-E5C1898297EE

Q28475529-22292885-3B31-498D-ABE0-BEA8793306F8

Q28475529-26DF7E05-0B51-4F70-9739-3EADF28B9649

Q28475529-3948660D-4833-4D28-9464-278409B04888

Q28475529-4DEFB4E9-098F-4A1B-BB51-D1DE6D42FCAA

Q28475529-52CB6BC5-6C6E-465A-AD21-1A5D7110481A

Q28475529-5EEF9210-7F23-4D4C-A591-E28FD341E8BD

P304

Q28475529-9D4C5291-3326-4D9A-894B-C9152E788E40

P31

Q28475529-7E523C36-B134-44FE-8CB0-C283B45AFEEE

P3181

Q28475529-7379C6DA-6C39-4FE8-BA53-2BA3D5DAE927

P356

Q28475529-E7C1D311-155E-4983-9C3B-FD96DD4D41FF

P407

Q28475529-7BCED44C-ECBC-4FA7-9897-26375F7E6007

P433

Q28475529-A4D8762F-B45A-465B-8231-90A151AEA994

P478

Q28475529-9212956E-3C2D-4278-A722-F949C60D7740

P577

Q28475529-D6935F87-A06C-4DCA-B368-704B28FBADD3

P5875

Q28475529-579BA9C3-5E79-444E-A0F4-4E4522E49582

P698

Q28475529-D849EAE9-66AF-4D1F-9DA7-E7FDE989006A

P921

Q28475529-74FE9F54-4CF4-405D-8B63-BDE2069B6D82

Q28475529-DFFDB1AF-9FB3-4D69-A55F-798E2CE25A50

P932

Q28475529-FCC30F2B-10AD-4E3F-AD21-5ECAF8814921

P3181

P356

JOURNAL.PONE.0005676

P1433

P1476

A novel two mode-acting inhibi ...... istance in cancer chemotherapy

@en

P2093

Hui Peng

http://www.w3.org/2001/XMLSchema#string

Jian-Ting Zhang

http://www.w3.org/2001/XMLSchema#string

Jing Qi

http://www.w3.org/2001/XMLSchema#string

Junkang Xu

http://www.w3.org/2001/XMLSchema#string

Yang Liu

http://www.w3.org/2001/XMLSchema#string

Youyun Yang

http://www.w3.org/2001/XMLSchema#string

Zhaomin Li

http://www.w3.org/2001/XMLSchema#string

Zizheng Dong

http://www.w3.org/2001/XMLSchema#string

P2860

Role of clathrin-mediated endocytosis in agonist-induced down-regulation of the beta2-adrenergic receptor

A distinct "side population" of cells with high drug efflux capacity in human tumor cells

Targeting multidrug resistance in cancer

A high-throughput cell-based assay for inhibitors of ABCG2 activity.

Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis.

New inhibitors of ABCG2 identified by high-throughput screening

Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo

Mechanistic and kinetic studies of inhibition of enzymes.

Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2).

Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy.

P304

e5676

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2823418

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0005676

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26250172

http://www.w3.org/2001/XMLSchema#string

P698

19479068

http://www.w3.org/2001/XMLSchema#string

P921

multiple drug resistance

P932

2682573

http://www.w3.org/2001/XMLSchema#string